A recent study conducted in the Netherlands, using data from a nationwide registry, has demonstrated that Dutch patients with stage IV EGFR-mutant NSCLC bearing an exon 19 deletion have significantly prolonged median overall survival compared to those with the L858R mutation8. Here, EGFR is linked to non-small cell lung carcinoma.